Bimiralisib
- Generic Name
- Bimiralisib
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F3N7O2
- CAS Number
- 1225037-39-7
- Unique Ingredient Identifier
- 6Z3QHB00LB
Overview
Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).
Background
Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath